血液代谢组学揭示炎症相关线粒体功能障碍可能是ACLF的潜在机制
该研究对650例肝硬化急性失代偿(AD)患者、181例慢加急性肝衰竭(ACLF)患者、43例代偿期肝硬化患者和29名健康人进行血清非靶向代谢组学分析,发现38种代谢物构成ACLF特异性血液指纹,其强度随ACLF分级升高,且与炎症标志物水平正相关。ACLF以强烈蛋白水解和脂解、氨基酸分解代谢、线粒体外葡萄糖代谢增强及线粒体脂肪酸β氧化受抑为特征,提示炎症相关线粒体功能障碍可能参与器官衰竭发生。
要点
- 38种代谢物构成的血液指纹对ACLF具有特异性,其强度随ACLF分级升高而增强。
- ACLF指纹强度与血浆炎症标志物TNF-α、sCD206和sCD163水平呈正相关。
- ACLF代谢特征包括线粒体ATP生成性脂肪酸β氧化受抑及线粒体外代谢增强。
核心结论
- 在ACLF中,强烈的全身性炎症与血液代谢物蓄积及主要代谢途径的深刻改变相关,尤其是线粒体能量生成受抑,这可能促进器官衰竭的发生。
研究设计与样本
- 研究采用液相色谱-高分辨质谱联用技术,对650例肝硬化急性失代偿(无ACLF)患者、181例ACLF患者、43例代偿期肝硬化患者和29名健康人的血清进行非靶向代谢组学分析。
主要发现
- 在137种注释代谢物中,100种在任意级别ACLF患者中相对AD患者升高,其中38种构成ACLF特异性血液代谢物指纹。
- ACLF患者中该指纹强度随ACLF分级升高而增强,且在伴肾衰竭与不伴肾衰竭患者中相似,提示其不仅反映肾脏排泄减少,也反映细胞代谢改变。
- ACLF-associated指纹强度越高,血浆炎症标志物TNF-α、sCD206和sCD163水平越高。
- ACLF代谢特征表现为强烈蛋白水解和脂解、氨基酸分解代谢、经糖酵解/戊糖磷酸/D-葡萄糖醛酸途径的线粒体外葡萄糖代谢、线粒体ATP生成性脂肪酸β氧化受抑,以及产生代谢毒素的线粒体外氨基酸代谢。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF), which develops in patients with cirrhosis, is characterized by intense systemic inflammation and organ failure(s). Because systemic inflammation is energetically expensive, its metabolic costs may result in organ dysfunction/failure. Therefore, we aimed to analyze the blood metabolome in patients with cirrhosis, with and without ACLF. METHODS: We performed untargeted metabolomics using liquid chromatography coupled to high-resolution mass spectrometry in serum from 650 patients with AD (acute decompensation of cirrhosis, without ACLF), 181 with ACLF, 43 with compensated cirrhosis, and 29 healthy individuals. RESULTS: Of the 137 annotated metabolites identified, 100 were increased in patients with ACLF of any grade, relative to those with AD, and 38 comprised a distinctive blood metabolite fingerprint for ACLF. Among patients with ACLF, the intensity of the fingerprint increased across ACLF grades, and was similar in patients with kidney failure and in those without, indicating that the fingerprint reflected not only decreased kidney excretion but also altered cell metabolism. The higher the ACLF-associated fingerprint intensity, the higher the plasma levels of inflammatory markers, tumor necrosis factor α, soluble CD206, and soluble CD163. ACLF was characterized by intense proteolysis and lipolysis; amino acid catabolism; extra-mitochondrial glucose metabolism through glycolysis, pentose phosphate, and D-glucuronate pathways; depressed mitochondrial ATP-producing fatty acid β-oxidation; and extra-mitochondrial amino acid metabolism giving rise to metabotoxins. CONCLUSIONS: In ACLF, intense systemic inflammation is associated with blood metabolite accumulation and profound alterations in major metabolic pathways, in particular inhibition of mitochondrial energy production, which may contribute to the development of organ failures. LAY SUMMARY: Acute-on-chronic liver failure (ACLF), which develops in patients with cirrhosis, is characterized by intense systemic inflammation and organ failure(s). Because systemic inflammation is energetically expensive, its metabolic costs may result in organ dysfunction/failure. We identified a 38-metabolite blood fingerprint specific for ACLF that revealed mitochondrial dysfunction in peripheral organs. This may contribute to organ failures.
引用
- Moreau R, Clària J, Aguilar F, et al. Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. J Hepatol. 2019. PMID: 31778751. doi:10.1016/j.jhep.2019.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。